Measuring the impact of monoclonal antibody therapies.

Lim, Ka Keat; Ng, Kenrick; Balachandran, Sathiyaa; Russell, Mark D; Boalch, Amy; Sinclair, Alasdair; Coker, Bolaji; Vinnakota, Krishna; Mansoor, Rashid; Douiri, Abdel; Marks, Lara V; Sacks, Steven

Lim, Ka Keat; Ng, Kenrick; Balachandran, Sathiyaa; Russell, Mark D; Boalch, Amy; Sinclair, Alasdair; Coker, Bolaji; Vinnakota, Krishna; Mansoor, Rashid; Douiri, Abdel; Marks, Lara V; Sacks, Steven.

Afiliação

Lim KK; Department of Population Health Sciences, King's College London, London, United Kingdom.
Ng K; Cancer Institute, University College London, London, United Kingdom.
Balachandran S; Centre for Rheumatic Diseases, King's College London, London, United Kingdom.
Russell MD; Centre for Rheumatic Diseases, King's College London, London, United Kingdom.
Boalch A; Centre for Rheumatic Diseases, King's College London, London, United Kingdom.
Sinclair A; University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Coker B; NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Vinnakota K; University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom.
Mansoor R; Department of Population Health Sciences, King's College London, London, United Kingdom.
Douiri A; Department of Population Health Sciences, King's College London, London, United Kingdom.
Marks LV; WhatisBiotechnology.org, Sevenoaks, United Kingdom.
Sacks S; Peter Gorer Department of Immunology, King's College London, London, United Kingdom.